Anika to Issue Second Quarter 2020 Financial Results and Business Highlights on Thursday, July 30
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced plans to release its second quarter 2020 financial results on July 30, 2020, after market close. A conference call will follow at 5:00 p.m. ET to discuss these results along with business highlights and outlook. Investors can access the call through a toll-free number or an international line, and a live audio webcast will also be available on Anika's website. The presentation will be archived on the site post-event.
- Scheduled release of Q2 2020 financial results indicates transparency and regular communication with investors.
- None.
BEDFORD, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products across the orthopedic early intervention continuum of care, today announced that the Company plans to issue its second quarter 2020 financial results after the close of the market on Thursday, July 30, 2020 and hold its investor conference call on the same day, Thursday, July 30, 2020, at 5:00 p.m. ET to discuss its financial results, business highlights, and outlook.
The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) and providing the conference ID number 10010333. A live audio webcast will be available in the "Investor Relations" section of Anika's website, www.anikatherapeutics.com. An accompanying slide presentation also can be accessed via the Anika Therapeutics website. The call will be archived and accessible on the same website shortly after its conclusion.
About Anika Therapeutics
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global, integrated joint preservation, restoration and regenerative solutions company based in Bedford, Massachusetts. Anika is committed to delivering a diverse array of products to improve the lives of patients, with a focus on osteoarthritis pain management, sports medicine and joint preservation, restoration and regeneration. The Company has close to three decades of global expertise commercializing innovative products across the orthopedic early intervention continuum of care. For more information about Anika, please visit www.anikatherapeutics.com.
50%; width: Anika Therapeutics, Inc. Sylvia Cheung, 781-457-9000 Chief Financial Officer investorrelations@anikatherapeutics.com | 50%; width: W2O Group Rachel Girard, 617-379-6760 rgirard@w2ogroup.com |
FAQ
When will Anika Therapeutics release its Q2 2020 financial results?
What time is the investor conference call for Anika Therapeutics?
How can I access the Anika Therapeutics conference call?